Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients

Ferumoxytol as a New, Safer, Easier-to-Administer Intravenous Iron: Yes or No?

(2008) Michael Auerbach   AMERICAN JOURNAL OF KIDNEY DISEASES

Improving efficiency and value in health care
Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice

(2008) Sunil Bhandari et al.   JOURNAL OF EVALUATION IN CLINICAL PRACTICE

High-Molecular Weight Iron Dextran: A Wolf in Sheep's Clothing?

(2008) G. M. Rodgers et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Intravenous Iron Exacerbates Oxidative DNA Damage in Peripheral Blood Lymphocytes in Chronic Hemodialysis Patients

(2008) K.-L. Kuo et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease

(2008) M. Auerbach et al.   KIDNEY INTERNATIONAL

Acute, severe and anaphylactoid reactions are very rare with low-molecular-weight iron dextran, CosmoFer(R)

(2008) O. Vaage-Nilsen   NEPHROLOGY DIALYSIS TRANSPLANTATION

Intravenous Iron, Inflammation, and Oxidative Stress: Is Iron a Friend or an Enemy of Uremic Patients?

(2007) Liliana Garneata   JOURNAL OF RENAL NUTRITION